[go: up one dir, main page]

NO20081068L - Kinolinderivater som antibakterielle midler - Google Patents

Kinolinderivater som antibakterielle midler

Info

Publication number
NO20081068L
NO20081068L NO20081068A NO20081068A NO20081068L NO 20081068 L NO20081068 L NO 20081068L NO 20081068 A NO20081068 A NO 20081068A NO 20081068 A NO20081068 A NO 20081068A NO 20081068 L NO20081068 L NO 20081068L
Authority
NO
Norway
Prior art keywords
alkyl
hydrogen
het
alkyloxy
alkylthio
Prior art date
Application number
NO20081068A
Other languages
English (en)
Other versions
NO342328B1 (no
Inventor
Jerome Emile George Guillemont
Koenraad Jozef Lodewij Andries
Anil Koul
Elisabeth Therese Jea Pasquier
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35768115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081068(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20081068L publication Critical patent/NO20081068L/no
Publication of NO342328B1 publication Critical patent/NO342328B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Anvendelse av en forbindelse for fremstilling av et medikament for behandling av en bakteriell infeksjon forutsatt at den bakterielle infeksjon er noe annet enn en mykobakteriell infeksjon, idet nevnte forbindelse er en forbindelse med formel (Ia) eller (Ib) et farmasøytisk akseptabelt syre- eller baseaddisjonssalt derav, et kvaternært amin derav, en stereokjemisk isomer form derav, en tautomer form derav eller en N-oksidform derav, hvori R1 er hydrogen, halogen, halogenalkyl, cyano, hydroksy, Ar, Het, alkyl, alkyloksy, alkyltio, alkyloksyalkyl, alkyltioalkyl, Ar-alkyl eller di(Ar)alkyl; p er 1, 2, 3 eller 4; R2 er hydrogen, hydroksy, tio, alkyloksy, alkyloksyalkyloksy, alkyltio, mono eller di(alkyl)amino eller et radikal med formel ; R3 er alkyl, Ar, Ar-alkyl, Het eller Het-alkyl; R4 er hydrogen, alkyl eller benzyl; R5 er hydrogen, halogen, halogenalkyl, hydroksy, Ar, alkyl, alkyloksy, alkyltio, alkyloksyalkyl, alkyltioalkyl, Ar-alkyl eller di(Ar)alkyl eller to nærliggende R5-radikaler kan være tatt sammen og danner sammen med fenylringen som de er bundet til, et naftyl; r er 1, 2, 3, 4 eller 5; R6 er hydrogen, alkyl, Ar eller Het; R7 er hydrogen eller alkyl; R8 er okso, eller R7 og R8 sammen form radikalet -CH=CH-N=; Z er CH2 eller C(=O). 66
NO20081068A 2005-08-03 2008-02-29 Kinolinderivater som antibakterielle midler NO342328B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107155 2005-08-03
PCT/EP2006/064847 WO2007014934A2 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterial agents

Publications (2)

Publication Number Publication Date
NO20081068L true NO20081068L (no) 2008-02-29
NO342328B1 NO342328B1 (no) 2018-05-07

Family

ID=35768115

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081068A NO342328B1 (no) 2005-08-03 2008-02-29 Kinolinderivater som antibakterielle midler

Country Status (30)

Country Link
US (1) US8691800B2 (no)
EP (1) EP1912649B1 (no)
JP (1) JP5208739B2 (no)
KR (1) KR101413094B1 (no)
CN (1) CN101277698B (no)
AP (1) AP2483A (no)
AR (1) AR054888A1 (no)
AU (1) AU2006274873B2 (no)
BR (1) BRPI0614099B8 (no)
CA (1) CA2615900C (no)
CY (1) CY1113535T1 (no)
DK (1) DK1912649T3 (no)
EA (1) EA014834B1 (no)
ES (1) ES2397358T3 (no)
HR (1) HRP20120910T1 (no)
IL (1) IL189140A (no)
JO (1) JO2837B1 (no)
ME (1) ME01485B (no)
MX (1) MX2008001601A (no)
MY (1) MY147637A (no)
NO (1) NO342328B1 (no)
NZ (1) NZ566012A (no)
PL (1) PL1912649T3 (no)
PT (1) PT1912649E (no)
RS (1) RS52606B (no)
SI (1) SI1912649T1 (no)
TW (1) TWI385168B (no)
UA (1) UA95911C2 (no)
WO (1) WO2007014934A2 (no)
ZA (1) ZA200801106B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2837B1 (en) 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JP5246715B2 (ja) * 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
JP6153604B2 (ja) 2012-04-27 2017-06-28 ヤンセン ファーマシューティカ エヌ.ベー. 抗菌性キノリン誘導体
JP6153603B2 (ja) 2012-04-27 2017-06-28 ヤンセン ファーマシューティカ エヌ.ベー. 抗菌性キノリン誘導体
BR122021024097B1 (pt) * 2016-03-07 2024-04-30 The Global Alliance For Tb Drug Development, Inc Composto antibacteriano, uso do mesmo e composição farmacêutica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
TW200409637A (en) * 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
SI2301544T1 (sl) * 2002-07-25 2013-01-31 Janssen Pharmaceutica, N.V. Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje
BRPI0507076B8 (pt) * 2004-01-23 2021-05-25 Janssen Pharmaceutica Nv quinolinas substituídas, seu processo de preparação, composição farmacêutica que as compreende e seu uso como inibidores micobacterianos
JO2837B1 (en) 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
EP1912649A2 (en) 2008-04-23
HK1124232A1 (zh) 2009-07-10
US20080227775A1 (en) 2008-09-18
WO2007014934A8 (en) 2007-05-18
RS52606B (sr) 2013-04-30
DK1912649T3 (da) 2013-01-21
TWI385168B (zh) 2013-02-11
WO2007014934A3 (en) 2007-04-05
BRPI0614099B8 (pt) 2021-05-25
BRPI0614099A2 (pt) 2011-03-09
NZ566012A (en) 2011-02-25
CN101277698B (zh) 2011-06-22
EP1912649B1 (en) 2012-10-10
MY147637A (en) 2012-12-31
AP2483A (en) 2012-10-01
JP2009503021A (ja) 2009-01-29
PL1912649T3 (pl) 2013-03-29
ME01485B (me) 2014-04-20
AU2006274873B2 (en) 2012-12-13
KR20080039961A (ko) 2008-05-07
WO2007014934A2 (en) 2007-02-08
PT1912649E (pt) 2013-01-14
AR054888A1 (es) 2007-07-25
NO342328B1 (no) 2018-05-07
CY1113535T1 (el) 2016-06-22
AU2006274873A1 (en) 2007-02-08
MX2008001601A (es) 2008-02-19
JO2837B1 (en) 2014-09-15
CA2615900A1 (en) 2007-02-08
IL189140A0 (en) 2008-08-07
ZA200801106B (en) 2009-09-30
TW200800971A (en) 2008-01-01
CA2615900C (en) 2014-12-09
JP5208739B2 (ja) 2013-06-12
SI1912649T1 (sl) 2013-01-31
KR101413094B1 (ko) 2014-07-01
UA95911C2 (ru) 2011-09-26
US8691800B2 (en) 2014-04-08
EA014834B1 (ru) 2011-02-28
BRPI0614099B1 (pt) 2019-11-12
ES2397358T3 (es) 2013-03-06
EA200800513A1 (ru) 2008-06-30
IL189140A (en) 2014-07-31
CN101277698A (zh) 2008-10-01
HRP20120910T1 (hr) 2012-12-31

Similar Documents

Publication Publication Date Title
NO20080955L (no) Kinolinderivater som antibakterielle midler
NO20081026L (no) Kinolinderivater som antibakterielle midler
NO20073823L (no) Kinolinderivater for behandlingen av latent tuberkulose
NO20081068L (no) Kinolinderivater som antibakterielle midler
NO20080499L (no) Kinolinderivater som antibakterielle midler
NO20080501L (no) Kinolinderivater som antibakterielle midler
WO2005070924A8 (en) Substituted quinolines and their use as mycobacterial inhibitors
NO20080481L (no) Kinolinderivater som antibakterielle midler
EA200500802A1 (ru) Лечение латентного туберкулёза
TH87466B (th) อนุพันธ์ควิโนลีน เป็นสารต้านแบคทีเรีย